Molecular pathogenesis of post-transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles

• Published in: PloS one Vol. 9; no. 8; p. e104164
• Main Authors: Wilflingseder, Julia, Sunzenauer, Judith, Toronyi, Eva, Heinzel, Andreas, Kainz, Alexander, Mayer, Bernd, Perco, Paul, Telkes, Gábor, Langer, Robert M, Oberbauer, Rainer
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 05-08-2014; Public Library of Science (PLoS)
• Subjects: Acute Kidney Injury - blood; Acute Kidney Injury - etiology; Acute Kidney Injury - genetics; Acute Kidney Injury - urine; Adult; Aged; Aged, 80 and over; Allografts; Apoptosis; Area Under Curve; Biology and life sciences; Biomarkers; Biomarkers - blood; Biomarkers - urine; Biopsy; Case-Control Studies; Databases, Genetic; Enzyme-Linked Immunosorbent Assay; Female; Gangrene; Gene expression; Gene Expression Profiling; Genome, Human; Genomes; Hemodialysis; Humans; Ischemia; Kidney transplantation; Kidney Transplantation - adverse effects; Kidneys; Leukocytes; Lipocalin; Male; Medicine and Health Sciences; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; Middle Aged; miRNA; Nephrology; Organs; Pathogenesis; Peptidase; Phenotype; Reproducibility of Results; Ribonucleic acid; RNA; RNA, Messenger - genetics; RNA, Messenger - metabolism; Secretory Leukocyte Peptidase Inhibitor - metabolism; Surgery; Tissue Donors; Transcription; Transplants & implants; Urine; Young Adult; Austria; California; Hungary; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0104164

Acute kidney injury (AKI) affects roughly 25% of all recipients of deceased donor organs. The prevention of post-transplant AKI is still an unmet clinical need. We prospectively collected zero-hour, indication as well as protocol kidney biopsies from 166 allografts between 2011 and 2013. In this cohort eight cases with AKI and ten matched allografts without pathology serving as control group were identified with a follow-up biopsy within the first twelve days after engraftment. For this set the zero-hour and follow-up biopsies were subjected to genome wide microRNA and mRNA profiling and analysis, followed by validation in independent expression profiles of 42 AKI and 21 protocol biopsies for strictly controlling the false discovery rate. Follow-up biopsies of AKI allografts compared to time-matched protocol biopsies, further baseline adjustment for zero-hour biopsy expression level and validation in independent datasets, revealed a molecular AKI signature holding 20 mRNAs and two miRNAs (miR-182-5p and miR-21-3p). Next to several established biomarkers such as lipocalin-2 also novel candidates of interest were identified in the signature. In further experimental evaluation the elevated transcript expression level of the secretory leukocyte peptidase inhibitor (SLPI) in AKI allografts was confirmed in plasma and urine on the protein level (p<0.001 and p = 0.003, respectively). miR-182-5p was identified as a molecular regulator of post-transplant AKI, strongly correlated with global gene expression changes during AKI. In summary, we identified an AKI-specific molecular signature providing the ground for novel biomarkers and target candidates such as SLPI and miR-182-5p in addressing AKI.